News

Accumetrics Inc. VerifyNow P2Y12 Test Bleeding Ischemic Events

Accumetrics Inc. announced an expansion in the intended use for the CE marked VerifyNow P2Y12 Test. Physicians can now use the test results to assess whether a patient may be at greater risk for...

Nanomix Inc. has initiated clinical testing in the United States to evaluate the omega-3 cardiac panel.  The panel quantitatively tests whole blood specimens for levels of cardiac troponin I...

AspirinWorks Test Kit

Corgenix Medical Corp. has announced that Atherotech Diagnostics Lab will carry its AspirinWorks Test for determining aspirin effect.

Alere Inc. announced the results of research presented at the American College of Cardiology’s 62nd Annual Scientific Session, which showed that a simple screening and management program can be...

Accumetrics Verify Now ACC 2013 Antiplatelet Therapy Blood Testing Pharmaceutica

Accumetrics Inc. announced the presentation of a series of important data that solidifies the clinical utility of platelet reactivity testing. Real world outcomes data in high-risk patients...

Laboratory Corporation of America Holdings (LabCorp) announced it has launched its clinical next generation sequencing assay, GeneSeq: Cardio for genetic causes of familial cardiac disease.

January has been a month of change for Abbott, and a senior medical devices analyst from GlobalData asserts that the company’s latest cardiac diagnostics product represents the first step in a...

Abbot Vascualr Architect Stat Blood Testing Point-of-Care Testing

An estimated 17 million people throughout the world die annually of cardiovascular diseases, specifically heart attacks or strokes. Time is a critical factor in diagnosing and treating people who...

Accumetrics VerifyNow II CE mark Antiplatelet Therapy

Accumetrics Inc. announced that its next generation VerifyNow II System has achieved CE marking for point-of-care measurement of platelet reactivity to antiplatelet agents. This marks the...

V-Chip Methodist Hospital Research Institute MD Anderson Cancer Center

A new device about the size of a business card could allow health care providers to test blood for insulin and other...

December 19, 2012 — The latest generation of diagnostic tests in development is expected to provide information that will be important to patient outcomes, potentially reducing the time to...

November 20, 2012 — The American College of Cardiology (ACC), in collaboration with several other professional societies, has released the first comprehensive consensus document outlining clinical...

CoaguChek XS Plus System Point of Care Testing Blood Testing

The U.S. Food and Drug Administration (FDA) has granted Clinical Laboratory Improvement Amendments (CLIA)-waived status to the Roche CoaguChek XS Plus system. The point-of-care...

Type 2 Diabetis Mellulitis Blood Testing Cardiac Diagnostics

LipoScience Inc., a highly innovative diagnostic company that is advancing patient care by developing high value proprietary blood tests using nuclear magnetic resonance (NMR) technology,...

September 28, 2012 — Accumetrics Inc., developer of the VerifyNow System, the first rapid and easy-to-use point-of-...

August 30, 2012 — Copeptin predicts prognosis in patients with heart failure, according to research presented at the European Society of Cardiology (ESC) congress this week Professor Stefan Störk...

August 9, 2012 — CardioDx Inc. announced that Palmetto GBA, a national contractor that administers Medicare benefits, has established coverage for the company’s Corus CAD gene...

July 26, 2012 — Transgenomic Inc. has announced that National Government Services, the designated Medicare fiscal intermediary in Connecticut, has confirmed coverage for its proprietary...

 

July 16, 2012 — LipoScience Inc., an in vitro diagnostic company developing clinical diagnostic tests using nuclear magnetic resonance (NMR) technology, announced...

July 16, 2012 — The U.S. Food and Drug Administration (FDA) notified healthcare professionals of a Class I recall of Alere Triage products. Identified lots may have significantly decreased...